One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway.
| SparkCures ID | 120 |
|---|---|
| Developed By | Merck Sharp & Dohme Corp. |
| Brand Name | Keytruda® |
| Generic Name | Pembrolizumab |
| Additional Names | MK-3475 |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.